- Home
- CLPR vs IXHL Comparison
CLPR vs IXHL Comparison
Compare CLPR & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPR | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | 171 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 49.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | IXHL |
|---|---|---|
| Price | $3.48 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.0K | ★ 23.8M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | ★ 10.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,179,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.37 | $0.08 |
| 52 Week High | $6.49 | $2.25 |
Technical Indicators
Market Signals| Indicator | CLPR | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 59.02 |
| Support Level | $3.37 | $0.35 |
| Resistance Level | $3.65 | $0.50 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 23.92 | 68.63 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.